Have a Question? 800.941.6884 · info@epigendx.com

MGMT Methylation Analysis

MGMT Methylation Analysis

MGMT Promoter Methylation In Glioblastoma

Glioblastoma is the most common form of primary brain cancer in adults, with a median survival rate of 12-15 months. Although nearly all glioblastomas recur, initial treatments may keep the tumor controlled for months or even years. MGMT promoter methylation has been shown to be associated with improved outcomes in glioblastoma patients, especially after treatment with alkylating chemotherapy.

This is due to the role of MGMT as a DNA repair enzyme. Inactivation of MGMT expression by methylation results in a decrease in DNA repair capabilities, leading to greater sensitivity to alkylating agents. To quantify CpG methylation within the MGMT gene promoter, researchers used bisulfite modification of tumor DNA and real-time PCR. Therefore, our MGMT methylation tests can help guide clinicians with treatment decisions.

MGMT Methylation helix image to section

Our Services

O6-methylguanine-DNA methyltransferase, known as MGMT, repairs damaged guanine nucleotides by transferring the methyl at O6 site of guanine to its cysteine residues, thus avoiding cell death, gene mutation and tumorigenesis caused by alkylating agents.

EpigenDx offers 4 validated MGMT methylation tests covering a total of 25 CpG sites in the Promoter, Exon 1, and Intron 1 regions of the MGMT gene:

chart showing human MGMT Methylation data
Human, MGMT – ASY470

Information: Human MGMG Methylation Assays

Assay ID Species Platform # of CpGs Region Order
ASY514A Human (Homo Sapiens) Bisulfite Pyrosequencing 6 Promoter Inquiry / Quote
ASY1518 Human (Homo Sapiens) Bisulfite Pyrosequencing 4 Intron 1 Inquiry / Quote
ASY470-FS1 Human (Homo Sapiens) Bisulfite Pyrosequencing 7 Exon 1 Inquiry / Quote
ASY470-FS2 Human (Homo Sapiens) Bisulfite Pyrosequencing 8 Exon 1 & Intron 1 Inquiry / Quote

O-6metilguanina scientific symbols

MGMT Methylation Analysis Service

In the treatment of glioblastoma multiforme, methylation of the O6-methylguanine DNA methyltransferase (MGMT) promoter has emerged as a major prognostic predictor. Methylation (or hypermethylation) of the MGMT gene promoter inhibits or inactivates the MGMT enzyme’s normal DNA-repair function, making tumors more vulnerable to radiotherapy or alkylating agent-based therapy.

  • Primers compatible with Pyrosequencing and Real-Time PCR based HRM technologies
  • Primers good for 300 reactions
  • Access to our knowledgeable and experienced customer service

MGMT Gene Methylation and Response to Alkylating Agents

Gene methylation is a DNA-based gene expression regulation method. Methylation levels in gene promoter regions can be aberrant or elevated in cancer (hypermethylated). This epigenetic change to DNA prevents the gene from performing its function, resulting in the protein encoded by the gene not being created or being produced at a low level.

O6-methylguanine-DNA methyltransferase (MGMT) is an important DNA repair enzyme in a healthy person. During the progression of cancer, this gene’s activity or function is usually lost. When the MGMT gene or function is lost, an individual is more vulnerable to DNA damage and tumor growth. However, once the cancer has progressed, the presence or absence of MGMT activity is no longer a factor.

Looking for a Custom Assay?

No problem, we’ve got you covered. EpigenDx provides custom assay design and analytical services with an assay database of thousands of Off-the-Shelf designs ready to go. Not only do we provide aggressive timelines with regular project updates, you will also get the highest quality technical support and consultation from design phase through project completion and data delivery.

EpigenDx

Experts in DNA Methylation

Ready To Get Started On Your Project?

YOU DON'T WANT TO MISS THIS!Epigenetics In The A.M. 2021 Event
Are you interested in DNA methylation, gene expression & gene regulation? Then this online event is for you! Let’s share our expertise on how to generate meaningful methylation data for publications, clinical research, biomarker discoveries & much more.

Two lucky winners will win the Raffle Giveaways!